Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial

British Journal of Cancer

Volumn 97, Issue 7, 2007, Pages 862-867

  Boige, V ^a   Raoul, J L ^b   Pignon, J P ^a   Bouche O ^c   Blanc, J F ^d   Dahan, L ^e   Jouve, J L ^f   Dupouy, N ^a   Ducreux, M ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b CENTRE EUGÈNE MARQUIS   (France)

^c REIMS UNIVERSITY HOSPITAL   (France)

^d University Hospital   (France)

^e TIMONE HOSPITAL   (France)

^f DIJON UNIVERSITY HOSPITAL   (France)

Author keywords

Capecitabine; Chemotherapy; Hepatocellular carcinoma; Oxaliplatin; Phase II clinical trial; XELOX

Indexed keywords

AMINOTRANSFERASE; BILIRUBIN; CAPECITABINE; OXALIPLATIN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DIARRHEA; DISEASE CONTROL; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; DEOXYCYTIDINE; DRUG COMBINATIONS; FEMALE; FLUOROURACIL; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 34948837268     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603956     Document Type: Article

References (30)

1. Cancer of the Liver Program (CLIP) Investigators (1998) A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the cancer of the liver program (CLIP) investigators. Hepatology 28: 751-755
2. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24: 4293-4300
3. Bearz A, Sorio R, Tommasi G, Toffoli G, Scarlone S, Beretta M, Frustaci S, Freschi A, Buonadonna A, Rupolo M, Tabaro G, Michieli M, Canale V, Cartei G (2001) Oxaliplatin and 5-FU in hepatocarcinoma. Proc Am Soc Clin Oncol 20: 148b (abstract 2343)
4. Borner MM, Dietrich D, Stupp R, Morant R, Honegger H, Wernli M, Herrmann R, Pestalozzi BC, Saletti P, Hanselmann S, Muller S, Brauchli P, Castiglione-Gertsch M, Goldhirsch A, Roth AD (2002) Phase II study of capecitabine and oxaliplatin in first and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol 20: 1759-1766
5. Brienza S, Vignoud J, Itzhaki M, Krikorian A (1995) Oxaliplatin: global safety in 682 patients. Proc Am Soc Clin Oncol 14: 209 (abstract 513)
6. Bruix J, Sala M, Llovet JM (2004) Chemoembolization for hepatocellular carcinoma. Gastroenterology 127(Suppl 1): S179-S188
7. Burroughs A, Hochhauser D, Meyer T (2004) Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. Lancet Oncol 5: 409-418
8. Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T, Debraud F, Figer A, Grossmann J, Sawada N, Schoffski P, Sobrero A, Van Cutsem E, Diaz-Rubio E (2004) XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 22: 2084-2091
9. Caussanel JP, Levi F, Brienza S, Misset JL, Itzhaki M, Adam R, Milano G, Hecquet B, Mathe G (1990) Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J Natl Cancer Inst 82: 1046-1050
10. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938-2947
11. Fleming TR (1982) One sample multiple testing procedure for phase II trials. Biometrics 38: 143-151
12. Frustaci S, Bearz A, Basso B, Tommasi LG, Buonadonna A, La Mura N, Cannizzaro R, Freschi A, Tumolo S, Toffoli G (2003) Efficacy of oxaliplatin and 5-fluorouracil in hepatocarcinoma (HCC). Proc Am Soc Clin Oncol 22: 335 (abstract 1346)
13. Kim SJ, Seo HY, Choi JG, Sul HR, Sung HJ, Park KH, Choi IK, Oh SC, Yoon SY, Seo JH, Choi CW, Kim BS, Shin SW, Kim YH, Kim JS (2006) Phase II study with a combination of epirubicin, cisplatin, UFT, and leucovorin in advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 57: 436-442
14. Lai CL, Wu PC, Chan GC, Lok AS, Lin HJ (1988) Doxorubicin vs no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 62: 479-483
15. Leung TW, Tang AM, Zee B, Yu SC, Lai PB, Lau WY, Johnson PJ (2002) Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. Cancer 94:421-427
16. Llovet J, Ricci S, Mazzaferro V, Hilgard P, Raoul J, Zeuzem S, Poulin-Costello M, Moscovici M, Voliotis D, Bruix J (2007) Randomized phase III trial of sorafenib vs placebo in patients with advanced hepatocellular carcinoma. Proc Am Soc Clin Oncol 25: 1384-1390. 962s (abstract LBA1)
17. Louafi S, Boige V, Ducreux M, Bonyhay L, Mansourbakht T, de Baere T, Asnacios A, Hannoun L, Poynard T, Taieb J (2007) Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Cancer 109: 1384-1390
18. Machin D, Campbell M, Fayers P, Pinol A (1997) Sample Size Tables for Clinical Studies. Oxford: Blackwell science, 2nd edn
19. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H (1998) Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34: 1274-1281
20. Okada S (1998) Chemotherapy in hepatocellular carcinoma. Hepatogastroenterology 45: 1259-1263
21. Park SH, Lee Y, Han SH, Kwon SY, Kwon OS, Kim SS, Kim JH, Park YH, Lee JN, Bang SM, Cho EK, Shin DB, Lee JH (2006a) Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma. BMC Cancer 6: 3
22. Park YH, Kim BS, Ryoo BY, Yang SH (2006b) A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer. Br J Cancer 94: 959-963
23. Parkin DM, Bray F, Ferlay J, Pisani P (2001) Estimating the world cancer burden: Globocan 2000. Int J Cancer 94: 153-156
24. Patt YZ, Hassan MM, Aguayo A, Nooka AK, Lozano RD, Curley SA, Vauthey JN, Ellis LM, Schnirer II, Wolff RA, Charnsangavej C, Brown TD (2004) Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer 101: 578-586
25. Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G, Donehower RC, Fitch T, Picus J, Erlichman C (2005) Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 23: 6657-6663
26. Schuller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, Utoh M, Mori K, Weidekamm E, Reigner B (2000) Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 45: 291-297
27. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216
28. Twelves C, Glynne-Jones R, Cassidy J, Schuller J, Goggin T, Roos B, Banken L, Utoh M, Weidekamm E, Reigner B (1999) Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. Clin Cancer Res 5: 1696-1702
29. Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, Bugat R, Findlay M, Frings S, Jahn M, McKendrick J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schmiegel WH, Seitz JF, Thompson P, Vieitez JM, Weitzel C, Harper P, Xeloda Colorectal Cancer Study Group. Xeloda Colorectal Cancer Study Group (2001) Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19: 4097-4106
30. Yeo W, Mok TS, Zee B, Leung TW, Lai PB, Lau WY, Koh J, Mo FK, Yu SC, Chan AT, Hui P, Ma B, Lam KC, Ho WM, Wong HT, Tang A, Johnson PJ (2005) A randomized phase III study of doxorubicin vs cisplatin/interferon alpha 2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 97: 1532-1538